Posted Mar. 24, 2017 at 6:18 a.m.

Premium Lock Humacyte's bioengineered blood vessel receives special FDA review designation

Published: 2017-03-24 06:18:35
Updated: 2017-03-24 06:18:35

Sample of a Humacyl vessel Sample of a Humacyl vessel. (Humacyte photo)

​Humacyte, a Research Triangle Park-based biotechnology company focused on regenerative medicine, has won one of the first Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders